DRI
48
-2
IVZ
48
2
FSLR
44
-2
AES
40
-5
APA
45
-3
LH
55
-3
CMA
64
3
NAVI
58
3
SYK
48
4
EMC
67
2
EIX
51
3
DAL
76
12
MOS
55
-7
AIG
54
-3
INTU
57
-3
VRSN
58
-2
PNR
65
3
AAL
53
17
DHR
64
2
EXPD
39
2
DRI
48
-2
IVZ
48
2
FSLR
44
-2
AES
40
-5
APA
45
-3
LH
55
-3
CMA
64
3
NAVI
58
3
SYK
48
4
EMC
67
2
EIX
51
3
DAL
76
12
MOS
55
-7
AIG
54
-3
INTU
57
-3
VRSN
58
-2
PNR
65
3
AAL
53
17
DHR
64
2
EXPD
39
2
Financhill
Back

Arbutus Biopharma 10K Form

Sell
36

ABUS
Arbutus Biopharma

Last Price:
$3.18
Seasonality Move:
15.77%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-07 10Q ABUS/Arbutus Biopharma Quarterly
2023-08-03 10Q ABUS/Arbutus Biopharma Quarterly
2023-05-04 10Q ABUS/Arbutus Biopharma Quarterly
2022-11-09 10Q ABUS/Arbutus Biopharma Quarterly
2022-08-04 10Q ABUS/Arbutus Biopharma Quarterly
2022-05-05 10Q ABUS/Arbutus Biopharma Quarterly

Receive ABUS News And Ratings

See the #1 stock for the next 7 days that we like better than ABUS

ABUS Financial Statistics

Sales & Book Value

Annual Sales: $6.2M
Cash Flow: $-13.4M
Price / Cash Flow: 0
Annual Sales: $0.41
Price / Book: 7.94

Profitability

EPS (TTM): -0.41000
Net Income (TTM): $-76.6M
Gross Margin: $-40.6M
Return on Equity: -73.56%
Return on Assets: -54.73%

Arbutus Biopharma Earnings Forecast

Key Arbutus Biopharma Financial Ratios

  • The Gross Profit Margin over the past 12 years for ABUS is -586.78%.
  • The Selling, General & Administrative Expenses for ABUS have been equal to 358.26% of Gross Profit Margin.
  • The Research & Development expenses have been 875.66% of Revenue.
  • The Net Earning history of ABUS is -1,133.04% of Total Revenues.
  • Per Share Earnings over the last 27 years have been positive in 17 years.

Arbutus Biopharma Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ABUS
CUSIP: 03879J
Website: arbutusbio.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 6.01
Quick Ratio: 5.86

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ABUS Technical Analysis vs Fundamental Analysis

Sell
36
Arbutus Biopharma (ABUS) is a Sell

Is Arbutus Biopharma a Buy or a Sell?

  • Arbutus Biopharma stock is rated a Sell
    The current Arbutus Biopharma [ABUS] share price is $3.28. The Score for ABUS is 36, which is 28% below its historic median score of 50, and infers higher risk than normal.